Home・Stock List・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Closed

SectorHealthcare

218 -6.98

Buy Sell

Overview

Share price change

24h

Current

Min

217.6

Max

234.38

Key metrics
By Trading Economics
Income	-36M -65M
Sales	-4.8M 191M
EPS	-1.26
Profit margin	-33.756
Employees	1,220
EBITDA	-36M -61M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+29.69% upside

Dividends
By Acuity
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	2.6B 12B
Previous open	224.98
Previous close	218

News Sentiment

By Acuity

28%

72%

92 / 340 Healthcare

Axsome Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

31 Jul 2026, 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30 Jul 2026, 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29 Jul 2026, 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28 Jul 2026, 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27 Jul 2026, 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

24 Jul 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

22 Jul 2026, 19:11 UTC

Axsome Therapeutics Inc shares are trading higher during Wednesday's session, reaching a high earlier before pulling back slightly amid increased market volume.

21 Jul 2026, 19:51 UTC

Social Media

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target, contributing to a rise in shares today.

20 Jul 2026, 21:21 UTC

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target. Shares are trading higher in after-market hours.

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

29.69% upside

12 Months Forecast

Average 282.71 USD 29.69%

High 380 USD

Low 242 USD

Based on 16 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Axsome Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

92 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.